Nyxoah S.A. (NYXH) Research

Nyxoah S.A. is a medical technology company dedicated to developing and bringing to market therapies for sleep disordered breathing conditions. Its flagship offering is the Genio system, a CE-Marked, patient-focused hypoglossal neurostimulation therapy that addresses moderate to severe obstructive sleep apnea. Established in 2009, the company maintains its headquarters in Mont-Saint-Guibert, Belgium.

Market snapshot

Symbol
NYXH
Price
$1.60
Day change
+0.63%
Market cap
$55.3M
P/E ratio
-0.70x
52-week range
1.26-8.588
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Next earnings
in 2 months
Analyst price target
$5.00

Peer companies

  • Perspective Therapeutics, Inc. (CATX)
  • Genfit S.A. (GNFT)
  • Invivyd, Inc. (IVVD)
  • KORU Medical Systems, Inc. (KRMD)
  • OmniAb, Inc. (OABI)
  • OraSure Technologies, Inc. (OSUR)
  • Prenetics Global Limited (PRE)
  • Neuronetics, Inc. (STIM)

Open Nyxoah S.A. (NYXH) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.